Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Diabetologia
Published in: Diabetologia 8/2011

01-08-2011 | Article

Diabetic retinopathy in type 1 diabetes—a contemporary analysis of 8,784 patients

Authors: H. P. Hammes, W. Kerner, S. Hofer, O. Kordonouri, K. Raile, R. W. Holl, on behalf of the DPV–Wiss Study Group

Published in: Diabetologia | Issue 8/2011

Login to get access

Abstract

Aims/hypothesis

The aim of this study was to analyse the risk profile for diabetic retinopathy under real-life conditions in a large cohort of patients with type 1 diabetes.

Methods

Patients (n = 18,891) with childhood, adolescent or adult onset of type 1 diabetes from the prospective German Diabetes Documentation System survey were analysed. A total of 8,784 patients fulfilled the inclusion criterion, which was availability of retinopathy status. Retinopathy grading (any retinopathy, advanced retinopathy), treatment regimens and risk factors were prospectively recorded and tested as covariates by Kaplan–Meier analysis and logistic regression.

Results

Any retinopathy was present in 27.4% and advanced retinopathy (severe non-proliferative or proliferative diabetic retinopathy) in 8.0% of the cohort. After 40 years of diabetes, the cumulative proportion of patients with any retinopathy and advanced retinopathy was 84.1% and 50.2%, respectively. In multiple regression analysis, risk factors for any retinopathy were diabetes duration (OR 1.167 per year), HbA1c >7.0% (53 mmol/mol) (OR 2.225), smoking (OR 1.295) and male sex (OR 1.187) (p < 0.0001 for all). Young age at onset (5 vs 15 years at disease onset) was protective (0.410, p < 0.0001). No glycaemic threshold was detected for retinopathy protection. Risk factors for advanced retinopathy were duration (1.124 per year, p < 0.0001), male sex (1.323, p = 0.0020), HbA1c >7.0% (53 mmol/mol) (1.499, p < 0.0001), triacylglycerol >1.7 mmol/l (1.398, p = 0.0013) and blood pressure  >140/90 mmHg (1.911, p < 0.0001).

Conclusions/interpretation

The prevalence of retinopathy remains significant in type 1 diabetes. Any improvement of metabolic control and non-smoking is protective, while hypertension affects progression to severe levels under real-life conditions. These data reinforce the validity of multifactorial concepts for morbidity protection in type 1 diabetes.
Appendix
Available only for authorised users
Literature
1.
Klein BE (2007) Overview of epidemiologic studies of diabetic retinopathy. Ophthalmic Epidemiol 14:179–183PubMedCrossRef
2.
Klein R, Klein BE, Moss SE, Davis MD, DeMets DL (1984) The Wisconsin Epidemiologic Study of Diabetic Retinopathy. II. Prevalence and risk of diabetic retinopathy when age at diagnosis is less than 30 years. Arch Ophthalmol 102:520–526PubMed
3.
The Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Research Group (2000) Retinopathy and nephropathy in patients with type 1 diabetes four years after a trial of intensive therapy. New Engl J Med 342:381–389CrossRef
4.
Klein R, Knudtson MD, Lee KE, Gangnon R, Klein BE (2008) The Wisconsin Epidemiologic Study of Diabetic Retinopathy: XXII the twenty-five-year progression of retinopathy in persons with type 1 diabetes. Ophthalmology 115:1859–1868PubMedCrossRef
5.
Hovind P, Tarnow L, Rossing K et al (2003) Decreasing incidence of severe diabetic microangiopathy in type 1 diabetes. Diabetes Care 26:1258–1264PubMedCrossRef
6.
Brinchmann-Hansen O, Dahl-Jorgensen K, Sandvik L, Hanssen KF (1992) Blood glucose concentrations and progression of diabetic retinopathy: the seven year results of the Oslo study. BMJ 304:19–22PubMedCrossRef
7.
Writing team for the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Research Group (2002) Effect of intensive therapy on the microvascular complications of type 1 diabetes mellitus. JAMA 287:2563–2569CrossRef
8.
Klein R, Klein BE, Moss SE, Cruickshanks KJ (1998) The Wisconsin Epidemiologic Study of Diabetic Retinopathy: XVII. The 14-year incidence and progression of diabetic retinopathy and associated risk factors in type 1 diabetes. Ophthalmology 105:1801–1815PubMedCrossRef
9.
Aiello LP, Cahill MT, Wong JS (2001) Systemic considerations in the management of diabetic retinopathy. Am J Ophthalmol 132:760–776PubMedCrossRef
10.
Cruickshanks KJ, Ritter LL, Klein R, Moss SE (1993) The association of microalbuminuria with diabetic retinopathy. The Wisconsin Epidemiologic Study of Diabetic Retinopathy. Ophthalmology 100:862–867PubMed
11.
Danne T, Kordonouri O, Enders I, Hovener G, Weber B (1998) Factors modifying the effect of hyperglycemia on the development of retinopathy in adolescents with diabetes. Results of the Berlin Retinopathy Study. Horm Res 50(Suppl 1):28–32PubMedCrossRef
12.
Kostraba JN, Dorman JS, Orchard TJ et al (1989) Contribution of diabetes duration before puberty to development of microvascular complications in IDDM subjects. Diabetes Care 12:686–693PubMedCrossRef
13.
Hecker W, Grabert M, Holl RW (1999) Quality of paediatric IDDM care in Germany: a multicentre analysis. German Paediatric Diabetology Group. J Pediatr Endocrinol Metab 12:31–38PubMedCrossRef
14.
Raile K, Galler A, Hofer S et al (2007) Diabetic nephropathy in 27,805 children, adolescents, and adults with type 1 diabetes: effect of diabetes duration, A1C, hypertension, dyslipidemia, diabetes onset, and sex. Diabetes Care 30:2523–2528PubMedCrossRef
15.
Schwab KO, Doerfer J, Hecker W et al (2006) Spectrum and prevalence of atherogenic risk factors in 27,358 children, adolescents, and young adults with type 1 diabetes: cross-sectional data from the German diabetes documentation and quality management system (DPV). Diabetes Care 29:218–225PubMedCrossRef
16.
Holl RW, Grabert M (2002) The quality circle: how to improve the outcome of paediatric diabetes care. Horm Res 57(Suppl 1):105–109PubMedCrossRef
17.
18.
Group Early Treatment Diabetic Retinopathy Study Research (1991) Grading diabetic retinopathy from stereoscopic color fundus photographs—an extension of the modified Airlie House classification. ETDRS report number 10. Ophthalmology 98:786–806
19.
Aiello LP, Gardner TW, King GL et al (1998) Diabetic retinopathy. Diabetes Care 21:143–156PubMed
20.
Diabetes Control and Complications Trial Research Group (1996) The absence of a glycemic threshold for the development of long-term complications: the perspective of the Diabetes Control and Complications Trial. Diabetes 45:1289–1298CrossRef
21.
Mancia G, Laurent S, Agabiti-Rosei E et al (2009) Reappraisal of European guidelines on hypertension management: a European Society of Hypertension Task Force document. J Hypertens 27:2121–2158PubMedCrossRef
22.
Keen H, Lee ET, Russell D, Miki E, Bennett PH, Lu M (2001) The appearance of retinopathy and progression to proliferative retinopathy: the WHO Multinational Study of Vascular Disease in Diabetes. Diabetologia 44(Suppl 2):S22–S30PubMedCrossRef
23.
24.
No authors listed (1994) Microvascular and acute complications in IDDM patients: the EURODIAB IDDM Complications Study. Diabetologia 37:278–285CrossRef
25.
Nathan DM, Zinman B, Cleary PA et al (2009) Modern-day clinical course of type 1 diabetes mellitus after 30 years' duration: the diabetes control and complications trial/epidemiology of diabetes interventions and complications and Pittsburgh epidemiology of diabetes complications experience (1983–2005). Arch Intern Med 169:1307–1316PubMedCrossRef
26.
Wong TY, Mwamburi M, Klein R et al (2009) Rates of progression in diabetic retinopathy during different time periods: a systematic review and meta-analysis. Diabetes Care 32:2307–2313PubMedCrossRef
27.
Pambianco G, Costacou T, Ellis D, Becker DJ, Klein R, Orchard TJ (2006) The 30-year natural history of type 1 diabetes complications: the Pittsburgh Epidemiology of Diabetes Complications Study experience. Diabetes 55:1463–1469PubMedCrossRef
28.
Kordonouri O, Danne T, Enders I, Weber B (1998) Does the long-term clinical course of type I diabetes mellitus differ in patients with prepubertal and pubertal onset? Results of the Berlin Retinopathy Study. Eur J Pediatr 157:202–207PubMedCrossRef
29.
Chaturvedi N, Sjolie AK, Stephenson JM et al (1998) Effect of lisinopril on progression of retinopathy in normotensive people with type 1 diabetes. The EUCLID Study Group. EURODIAB Controlled Trial of lisinopril in insulin-dependent diabetes mellitus. Lancet 351:28–31PubMedCrossRef
30.
Zhang JZ, Xi X, Gao L, Kern TS (2007) Captopril inhibits capillary degeneration in the early stages of diabetic retinopathy. Curr Eye Res 32:883–889PubMedCrossRef
31.
Chaturvedi N, Porta M, Klein R et al (2008) Effect of candesartan on prevention (DIRECT-Prevent 1) and progression (DIRECT-Protect 1) of retinopathy in type 1 diabetes: randomised, placebo-controlled trials. Lancet 372:1394–1402PubMedCrossRef
32.
No authors listed (1995) The relationship of glycemic exposure (HbA1c) to the risk of development and progression of retinopathy in the diabetes control and complications trial. Diabetes 44:968–983CrossRef
33.
Danne T, Kordonouri O, Hovener G, Weber B (1997) Diabetic angiopathy in children. Diabet Med 14:1012–1025PubMedCrossRef
34.
Klein BE, Moss SE, Klein R (1990) Is menarche associated with diabetic retinopathy? Diabetes Care 13:1034–1038PubMedCrossRef
35.
Olsen BS, Sjolie AK, Hougaard P et al (2004) The significance of the prepubertal diabetes duration for the development of retinopathy and nephropathy in patients with type 1 diabetes. J Diab Complications 18:160–164CrossRef
36.
Hietala K, Harjutsalo V, Forsblom C, Summanen P, Groop PH (2010) Age at onset and the risk of proliferative retinopathy in type 1 diabetes. Diabetes Care 33:1315–1319PubMedCrossRef
37.
Moss SE, Klein R, Klein BE (1996) Cigarette smoking and ten-year progression of diabetic retinopathy. Ophthalmology 103:1438–1442PubMed
38.
Muhlhauser I, Bender R, Bott U et al (1996) Cigarette smoking and progression of retinopathy and nephropathy in type 1 diabetes. Diabet Med 13:536–543PubMedCrossRef
39.
Muhlhauser I, Sawicki P, Berger M (1986) Cigarette-smoking as a risk factor for macroproteinuria and proliferative retinopathy in type 1 (insulin-dependent) diabetes. Diabetologia 29:500–502PubMedCrossRef
40.
Nordwall M, Arnqvist HJ, Bojestig M, Ludvigsson J (2009) Good glycemic control remains crucial in prevention of late diabetic complications—the Linkoping Diabetes Complications Study. Pediatr Diab 10:168–176CrossRef
41.
Vergouwe Y, Soedamah-Muthu SS, Zgibor J et al (2010) Progression to microalbuminuria in type 1 diabetes: development and validation of a prediction rule. Diabetologia 53:254–262PubMedCrossRef
42.
Barth JL, Yu Y, Song W et al (2007) Oxidised, glycated LDL selectively influences tissue inhibitor of metalloproteinase-3 gene expression and protein production in human retinal capillary pericytes. Diabetologia 50:2200–2208PubMedCrossRef
43.
Chaturvedi N, Sjoelie AK, Porta M et al (2001) Markers of insulin resistance are strong risk factors for retinopathy incidence in type 1 diabetes. Diabetes Care 24:284–289PubMedCrossRef
44.
Sjolie AK, Stephenson J, Aldington S et al (1997) Retinopathy and vision loss in insulin-dependent diabetes in Europe. The EURODIAB IDDM Complications Study. Ophthalmology 104:252–260PubMed
45.
Olsen BS, Sjolie A, Hougaard P et al (2000) A 6-year nationwide cohort study of glycaemic control in young people with type 1 diabetes. Risk markers for the development of retinopathy, nephropathy and neuropathy. Danish Study Group of Diabetes in Childhood. J Diab Complications 14:295–300CrossRef
Metadata
Title
Diabetic retinopathy in type 1 diabetes—a contemporary analysis of 8,784 patients
Authors
H. P. Hammes
W. Kerner
S. Hofer
O. Kordonouri
K. Raile
R. W. Holl
on behalf of the DPV–Wiss Study Group
Publication date
01-08-2011
Publisher
Springer-Verlag
Published in
Diabetologia / Issue 8/2011
Print ISSN: 0012-186X
Electronic ISSN: 1432-0428
DOI
https://doi.org/10.1007/s00125-011-2198-1

Other articles of this Issue 8/2011

Diabetologia 8/2011 Go to the issue

Article

Low-dose glucocorticoid treatment affects multiple aspects of intermediary metabolism in healthy humans: a randomised controlled trial

Article

Increased abundance of the adaptor protein containing pleckstrin homology domain, phosphotyrosine binding domain and leucine zipper motif (APPL1) in patients with obesity and type 2 diabetes: evidence for altered adiponectin signalling

Article

Sex-related differences in the long-term risk of microvascular complications by age at onset of type 1 diabetes

Article

Hepatic steatosis does not cause insulin resistance in people with familial hypobetalipoproteinaemia

Article

Characterisation of glyoxalase I in a streptozocin-induced mouse model of diabetes with painful and insensate neuropathy

Article

Disturbed subjective sleep characteristics in adult patients with long-standing type 1 diabetes mellitus
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits